Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women (RELEASE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03446781
Recruitment Status : Completed
First Posted : February 27, 2018
Last Update Posted : October 3, 2018
Sponsor:
Information provided by (Responsible Party):
Endo Pharmaceuticals

Brief Summary:
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the subject using the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed, subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days 1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the buttocks will be at the discretion of the Investigator. End of study will occur at study day 71.

Condition or disease Intervention/treatment Phase
Edematous Fibrosclerotic Panniculopathy (Cellulite) Biological: EN3835 Biological: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 422 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)
Actual Study Start Date : February 8, 2018
Actual Primary Completion Date : September 26, 2018
Actual Study Completion Date : September 26, 2018

Arm Intervention/treatment
Active Comparator: EN3835 Active
EN3835 0.84mg (Collagenase Clostridium Histolyticum)
Biological: EN3835
Collagenase clostridium histolyticum

Placebo Comparator: Placebo
Placebo
Biological: Placebo
Placebo




Primary Outcome Measures :
  1. Improvement in severity of target buttock from baseline of at least 2 levels of severity in Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) [ Time Frame: 71 days ]
    Scale is 5-levels, 0=None to 4=Severe

  2. Improvement in severity of target buttock from baseline of at least 2 levels of severity in Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) [ Time Frame: 71 days ]
    Scale is 5-levels, 0=None to 4=Severe


Secondary Outcome Measures :
  1. Proportion of 1-level PR-PCSS responders defined as subjects with ≥1-level improvement in PR-PCSS severity rating of the target buttock [ Time Frame: 71 Days ]
    Scale is 5-levels, 0=None to 4=Severe

  2. Proportion of 2-level PR-PCSS responders defined as subjects with ≥2-level improvement in PR-PCSS severity rating of target buttock [ Time Frame: 71 Days ]
    Scale is 5-levels, 0=None to 4=Severe

  3. Proportion of 1-level composite responders of target buttock (subjects with improvement in severity from baseline of at least 1 level of severity in CR-PCSS and improvement of severity from baseline of at least 1 level of severity in the PR-PCSS) [ Time Frame: 71 Days ]
    Scales are 5-levels, 0=None to 4=Severe

  4. Proportion of 2-level composite responders of the non-target buttock [ Time Frame: 71 Days ]
    Scales are 5-levels, 0=None to 4=Severe

  5. Proportion of 1-level Subject Self Rating Scale responders defined as subjects who were at least slightly satisfied (Scale is 7 levels, 0=Extremely Dissatisfied to 6=Extremely Satisfied) [ Time Frame: 71 Days ]
  6. Change from baseline (Day 1) of the Patient Reported Cellulite Impact Scale total score (Scale 11 levels; 0=Not at All to 10=Extremely) [ Time Frame: 71 Days ]
  7. Proportion of 1-level Subject Global Aesthetic Improvement Scale (S-GAIS) responders defined as subjects with ≥1-level improvement (improved, much improved or very much improved) in S-GAIS assessment of the target buttock [ Time Frame: 71 Days ]
  8. Proportion of 2-level S-GAIS responders defined as subjects with ≥2-level improvement (much improved or very much improved) in the assessment of the target buttock [ Time Frame: 71 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Voluntarily sign and date an informed consent agreement
  2. Be a female ≥18 years of age
  3. At Screening visit, have 2 bilateral buttocks with each buttock having:

    1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and
    2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)
  4. At Day 1 visit, have 2 bilateral buttocks with each buttock having:

    1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and
    2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)
  5. Be willing to apply sunscreen to the buttocks before each exposure to the sun while participating in the study (ie, Screening through end of study)
  6. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at Screening
  7. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test before injection of study drug and be using a stable and effective contraception method (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the Investigator; or post-menopausal for at least 1 year; or be surgically sterile
  8. Be willing and able to cooperate with the requirements of the study
  9. Be able to read, complete and understand the patient-reported outcomes rating instruments in English

Exclusion Criteria:

  1. Has any of the following systemic conditions:

    1. Coagulation disorder
    2. Evidence or history of malignancy (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years
    3. History of keloidal scarring or abnormal wound healing
    4. Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. Any questions about concurrent diseases should be discussed with the Medical Monitor
    5. Evidence of clinically significant abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values
  2. Has any of the following local conditions in the areas to be treated:

    1. History of lower extremity thrombosis or post-thrombosis syndrome
    2. Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated
    3. Inflammation or active infection
    4. Severe skin laxity, flaccidity, and/or sagging
    5. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer
    6. Has a tattoo and/or a mole located within 2 cm of the site of injection
  3. Requires the following concomitant medications before or during participation in the trial:

    a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug

  4. Has used any of the following for the treatment of EFP on a buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:

    1. Liposuction in a buttock during the 12-month period before injection of study drug
    2. Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; buttock implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) within a buttock during the 12-month period before injection of study drug
    3. Any investigational treatment for EFP on a buttock during the 12-month period before the injection of study drug
    4. Endermologie or similar treatments within a buttock during the 6-month period before injection of study drug
    5. Massage therapy within a buttock during the 3-month period before injection of study drug
    6. Creams (eg, Celluvera™, TriLastin®) and/or home therapies to prevent or mitigate EFP within a buttock during the 2-week period before injection of study drug
  5. Is presently nursing or providing breast milk
  6. Intends to become pregnant during the study
  7. Intends to initiate an intensive sport or exercise program during the study
  8. Intends to initiate a weight reduction program during the study
  9. Intends to use tanning spray or tanning booths during the study
  10. Has received an investigational drug or treatment within 30 days before injection of study drug
  11. Has a known systemic allergy to collagenase or any other excipient of study drug
  12. Has received any collagenase treatments at any time prior to treatment
  13. Was a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, and/or EN3835-205
  14. Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03446781


  Show 25 Study Locations
Sponsors and Collaborators
Endo Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Michael McLane Endo Pharmaceuticals

Layout table for additonal information
Responsible Party: Endo Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03446781     History of Changes
Other Study ID Numbers: EN3835-303
First Posted: February 27, 2018    Key Record Dates
Last Update Posted: October 3, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Cellulite
Edema
Skin Manifestations
Signs and Symptoms